Finger pushing


Author: Bhanvi Satija

  • Gilead to buy CymaBay for $4.3 billion in bets on liver disease treatment

    By Bhanvi Satija (Reuters) -Gilead Sciences has agreed to buy CymaBay Therapeutics for $4.3 billion, gaining access to an experimental liver disease treatment with blockbuster potential as the U.S. drugmaker looks beyond its older HIV drugs for growth. Shares of the Newark, California-based drug developer jumped 24.6% to a record high of $32.01 in morning…

  • Drugmakers kick off industry conference with two cancer deals

    Drugmakers kick off industry conference with two cancer deals

    By Bhanvi Satija and Sriparna Roy (Reuters) – Johnson & Johnson and Merck on Monday announced plans to buy cancer therapy developers on the first day of a major U.S. healthcare conference, igniting what industry participants hope will be a strong year for deals after a solid end to 2023. Deals announced on Monday had…

  • Bristol Myers to buy RayzeBio for $4.1 billion in targeted cancer therapy push

    Bristol Myers to buy RayzeBio for $4.1 billion in targeted cancer therapy push

    By Bhanvi Satija (Reuters) -Bristol Myers Squibb said on Tuesday it would buy RayzeBio for about $4.1 billion to bolster its cancer drug business, marking the second multi-billion dollar deal struck by the drugmaker in less than a week. Bristol Myers had announced a $14 billion buyout of schizophrenia drug developer Karuna Therapeutics on Friday,…

  • Biogen cuts profit forecast on Alzheimer’s drug launch, deal costs

    By Bhanvi Satija and Mariam Sunny (Reuters) -Biogen on Wednesday cut its annual profit forecast to below Wall Street estimates due to higher costs associated with the launch of Alzheimer’s drug Leqembi and its $6.5 billion Reata Pharmaceuticals acquisition, and shares fell more than 4%. About 800 people were currently being treated with Leqembi, Biogen’s…

  • Biogen to buy Reata for $6.5 billion to bulk up rare disease portfolio

    By Manas Mishra and Bhanvi Satija (Reuters) -Biogen agreed to buy rare disease drugmaker Reata Pharmaceuticals for nearly $6.5 billion, the first large acquisition under new CEO Christopher Viehbacher as he seeks to return the drugmaker to growth. Viehbacher was hired in November to put Biogen back on a growth path after a series of…

  • Eli Lilly’s weak diabetes drugs sales cloud 2023 profit forecast

    By Bhanvi Satija and Patrick Wingrove (Reuters) -Eli Lilly and Co missed Wall Street estimates for fourth-quarter sales of both the closely-watched new type 2 diabetes drug Mounjaro and its blockbuster treatment for the condition, overshadowing a better-than-expected 2023 profit forecast, and shares fell 6%. The U.S. drugmaker has been leaning on Mounjaro to soften…

  • J&J expects inflation, China COVID hit to carry into 2023

    J&J expects inflation, China COVID hit to carry into 2023

    By Bhanvi Satija and Manas Mishra (Reuters) – Johnson & Johnson on Tuesday said it sees the impact from high inflation carrying into 2023 and expects China’s major COVID-19 outbreak to dent sales at its medical devices unit in the first half of the year. Inflation has hurt demand for consumer health products and driven…

  • Humana profit beats as medical costs ease on slow elective-care rebound

    By Raghav Mahobe and Bhanvi Satija (Reuters) -Humana Inc beat third-quarter profit estimates on Wednesday, as a sluggish recovery in elective procedures helped the health insurer keep medical costs in check. Rivals such as UnitedHealth Group Inc and Elevance Health have also benefited from lower-than-expected medical costs, prompting them to raise their full-year forecasts. Humana…

  • Cigna boosts forecast as lower costs drive profit beat

    By Mrinalika Roy and Bhanvi Satija (Reuters) -Cigna Corp on Thursday raised its annual earnings forecast after topping quarterly profit estimates as a slow recovery in non-urgent procedures lowers medical expenses, sending the insurer’s shares up about 5%. Cigna’s robust performance rounded off a strong quarter for health insurers that have seen their fortunes fluctuate…

Welcome Back.

Streak: 9 days i

Stories you've missed since your last login:

Stories you've saved for later:

Recommended stories based on your interests:

Edit my interests